Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/IIa Study to Assess the Safety, Tolerability, Biodistribution and Pharmacodynamic of T3011 Herpes Virus Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors.

Next Previous
Search
Trial Profile

A Phase I/IIa Study to Assess the Safety, Tolerability, Biodistribution and Pharmacodynamic of T3011 Herpes Virus Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors.

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs T 3011 (Primary)
  • Indications Advanced breast cancer; Breast cancer; Cancer metastases; Head and neck cancer; Lung cancer; Malignant melanoma; Oesophageal cancer; Sarcoma; Skin cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man
  • Sponsors Immvira Pharma

    • Most Recent Events

    • 15 Mar 2024 According to an Immvira Pharma media release, company announced that the U.S. Food and Drug Administration has granted Fast Track designation for MVR-T3011 IT (intratumoral injection) for the treatment of recurrent or metastatic head and neck squamous cell cancer with disease progression after platinum-based chemotherapy and at least one prior line of anti-PD1/PDL1 therapy. Supporting evidence for this request was derived from Phase I/II trials conducted in both the United States and China.
    • 06 Jun 2023 Results (As of 18 Jan. 2023, n=90) assessing safety and efficacy of T3011 in advanced solid tumorspresented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2023 According to a ImmVira pharma media release, the company presented results from Phase I/II clinical trials of MVR-T3011 IT (intratumoral injection) in China with all selected to be published (1 chosen for poster discussion) at the 2023 American Society for Clinical Oncology Annual Meeting (ASCO 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top